DOI: 10.5061/dryad.905qfttx3
title: Data from: A longitudinal assessment of the antibody response to SARS-CoV-2 infection in the New Mexican population

description: While many studies have assessed immune responses to SARS-CoV-2 infection,
 none have studied functional antibody responses before and after
 vaccination of exposed patients in New Mexico in the United States. Here,
 we evaluate antibody binding, antibody neutralization, and
 antibody-dependent cell-mediated cytotoxicity (ADCC) responses from
 convalescent patients between 2020 and 2021. Our results indicate that
 binding, neutralizing, and ADCC titers remained durable over an estimated
 4-month period or were boosted by vaccination. Antibody binding titer
 stability was comparable to that of antibodies against four common
 viruses. Overall, these data shed light on functional antibody responses
 to SARS-CoV-2 in pre-alpha variant waves in New Mexico.
description: # Data from: A longitudinal assessment of the antibody response to
 SARS-CoV-2 infection in the New Mexican population Dataset DOI:
 [10.5061/dryad.905qfttx3](10.5061/dryad.905qfttx3) ## Description of the
 data and file structure These experiments were conducted to assess
 antibody responses (binding, functional, and neutralizing) against
 SARS-CoV-2 in 2020-2021 in New Mexican patients and to assess the effect
 of vaccination on pre-existing antibody titers. All missing values are
 represented as N/A. ### Files and variables #### File: Figure_1_data.xlsx
 **Description:**  * Column A:  patient number * Column B:  ELISA titers
 agaSARS-CoV-2CoV-2 from the first blood draw of unvaccinated patients *
 Column C:  ELISA titers againSARS-CoV-2V-2 from the second blood draw of
 unvaccinated patients * Column D:  ELISA titers agaSARS-CoV-2CoV-2 from
 the first blood draw of unvaccinated patients that were later vaccinated *
 Column E:  ELISA titers against SARS-CoV-22 from the second blood draw of
 patients who were vaccinated between draws 1 and 2 IgG concentrations were
 calculated utilizing the trendline equation created using the standard’s
 included in the kit. #### File: Figure_2_data_revised.xlsx
 **Description:**  * Column A:  patient number * Column B:  Fold change in
 ELISA titers against SARS-CoV-2 between blood draws 1 and 2 * Column C: 
 Fold change in ELISA titers against adenovirus between blood draws 1 and 2
 * Column D:  Fold change in ELISA titers against cytomegalovirus between
 blood draws 1 and 2 * Column E:  Fold change in ELISA titers against
 measles virus between blood draws 1 and 2 * Column F:  Fold change in
 ELISA titers against common cold coronavirus hCoV 299E between blood draws
 1 and 2 Fold change in IgG concentration between draw 1 and draw 2 was
 calculated for each patient. #### File: Figure_3_data_revised.xlsx
 **Description:**  * Column A:  patient number * Column B:  neutralizing
 antibody titers agaiSARS-CoV-2oV-2 from the first blood draw of
 unvaccinated patients * Column C:  neutralizing antibody titers
 agaSARS-CoV-2CoV-2 from the second blood draw of unvaccinated patients *
 Column D:  neutralizing antibody titers against agSARS-CoV-2 CoV-2 from
 the first blood draw of unvaccinated patients that were later vaccinated *
 Column E:  neutralizing antibody titers against agSARS-CoV-2 CoV-2 from
 the second blood draw of patients who were vaccinated between draws 1 and
 2 Neutralization of SARS-CoV-2 live virus was assessed through a PRNT.
 #### File: Figure_4_data_revised.xlsx **Description:**  * Column A: 
 patient number * Column B:  antibody-dependent cell-mediated cytotoxicity
 (ADCC) titers agaiSARS-CoV-2oV-2 from the first blood draw of unvaccinated
 patients * Column C:  antibody-dependent cell-mediated cytotoxicity titers
 against againsSARS-CoV-2-2 from the second blood draw of unvaccinated
 patients * Column D:  antibody-dependent cell-mediated cytotoxicity titers
 against SARS-CoV-22 from the first blood draw of unvaccinated patients who
 were later vaccinated * Column E:  antibody-dependent cell-mediated
 cytotoxicity titers against agSARS-CoV-2 CoV-2 from the second blood draw
 of patients who were vaccinated between draws 1 and 2 ADCC activity was
 assessed using an ADCC luciferase reporter assay. ## Code/software Data
 are Excel worksheets ## Access information Other publicly accessible
 locations of the data: * None Data was derived from the following sources:
 * None ## Human subjects data We received explicit informed consent from
 the study participants to publish de-identified data in the public domain.
 The data was de-identified by blinding experimentalists from PHI and
 assigning a anonymized number to each patient.